Adverse Drug Reaction Update
- PDF / 111,699 Bytes
- 8 Pages / 504 x 720 pts Page_size
- 39 Downloads / 207 Views
Adv Drug React Toxicol Rev 2002; 21 (4): 253-260 0964-198X/02/0004-0253/$25.00/0 © Adis International Limited. All rights reserved.
Adverse Drug Reaction Update Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. ‘Zyban’ Safety Update from the UK Medicines Control Agency . . . . . . . . . . . . 2. Risk Factors for Macrolide-Associated Torsade de Pointes . . . . . . . . . . . . . . . . 3. Decrease in Left Ventricular Ejection Fraction Predictive of Doxorubicin Cardiotoxicity 4. Olanzapine Increases Risk of Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. Alprazolam Seriously Impairs Driving Performance . . . . . . . . . . . . . . . . . . . . 6. Estrogen-Only Hormone Replacement Therapy Increases Risk of Ovarian Cancer . . 7, Low-Dose Epirubicin may cause Long-Term Cardiac Damage . . . . . . . . . . . . . 8. Kavain Withdrawn in Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9. Thioridazine: Risk of Sudden Death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10. Alosetron Reintroduction Debated . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11. Depot Medroxyprogesterone Increases Risk of Cardiovascular Disease? . . . . . . . 12. Vigabatrin: Visual Field Constriction in Paediatric Patients . . . . . . . . . . . . . . . . 13. Childhood Vaccination not Associated with Elevated Risk of Asthma . . . . . . . . .
. . . . . . . . . . . . . .
. . . . . . . . . . . . . .
. . . . . . . . . . . . . .
. . . . . . . . . . . . . .
. . . . . . . . . . . . . .
. . . . . . . . . . . . . .
253 253 254 254 255 255 256 256 257 257 258 259 259 260
Increasing numbers of articles on adverse drug reactions are published in a wide range of medical journals. To help keep you up-to-date with the latest advances worldwide on all aspects of adverse drug reactions, this section of the journal brings you information selected from the drug safety alerting service Reactions Weekly1. The following reports are selected from the latest issues, summarizing the most important clinical studies, adverse reaction news, and expert opinion pieces published across a broad range of literature sources.
1. ‘Zyban’ Safety Update from the UK Medicines Control Agency The UK Medicines Control Agency (MCA) has issued a new safety update for ‘Zyban’ (bupropion) that includes a reminder to prescribers that ‘Zyban’ is contraindicated in patients with current or previous seizure disorders. Up to 24 July 2002 the UK MCA had received
a total of 7630 reports of suspected adverse reactions associated with ‘Zyban’ via the Yellow Card Scheme. However, it is noted that a number of these reports may be associated with factors such as nicotine withdrawal, other illnesses or concomitant medications. It is estimated that up to 31 March 2002, 540 000 patients in the UK had received ‘Zyban’.
1 Reactions Weekly is the complete drug safety alerting service and summarises information selected from over 1600 biomedical journals. This newsletter is produced by Ad
Data Loading...
